Conversely, minimal activity from anti-HER2 therapy was evident in an open label phase II trial from Pestrin et al. In this prospective feasibility study, patients with recurrent disease after previous HER2− primary breast cancer were screened for the presence of CTCs. Here, ERBB2 is linked to breast cancer.